This single-center, crossover study aims to investigate the effects of the new OptiNIV oronasal mask used during NIV in COPD patients with respiratory acidosis following an exacerbation. The goal is to evaluate whether the clinical benefits, in terms of reducing PaCO2 levels, are greater with the new mask compared to a traditional one (Visairo Mask).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Evaluation of the effects of the OptiNIV oronasal mask on partial pressure of carbon dioxide (PaCOâ‚‚) levels in patients with severe COPD exacerbation requiring treatment with non-invasive mechanical ventilation.
Timeframe: T0 (baseline), T1 ( + 1 hour), T2 ( + 2 hours), T3 (+ 3 hours).